• Gui-Qian Wang, Xing Liao, and Yan-Ming Xie.
• Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
• Zhongguo Zhong Yao Za Zhi. 2016 Dec 1; 41 (24): 4483-4487.

AbstractStudies on post-marketing drug surveillance have become increasingly important in recent years. In particular, many researchers for traditional Chinese medicine have paid more attention to the safety of post-marketing Chinese patent medicines. Observational studies, like cohort study, registry study, and intensive hospital monitoring, were conducted to collect data on safety information. How to accurately report and assess these studies and let readers to completely understand relevant published reports and obtain transparent information about its methodology and findings remain unsolved. According to the reporting guidelines made by EQUATOR, our research team drafted a framework based on a four-year study by reference to relevant rules, guidelines and standards all over the world in the field of drug safety evaluation. Besides, we consulted relevant experts in this field and formed a framework on how to report post-marketing safety studies of Chinese patent medicines. There were seven core components, namely drug, population, setting, design, quality, adverse reaction and statistics, which could be abbreviated to DPSDQAS. We introduced the framework here to provide reference for future researchers.Copyright© by the Chinese Pharmaceutical Association.

13 keywords...

hide…